Scarred glomeruli in the kidney of a person with diabetic nephropathy
|Classification and external resources|
|ICD-10||E10.2, E11.2, E12.2, E13.2, E14.2|
Diabetic nephropathy (or diabetic kidney disease) is a progressive kidney disease caused by damage to the capillaries in the kidneys' glomeruli. It is characterized by nephrotic syndrome and diffuse scarring of the glomeruli. It is due to longstanding diabetes mellitus, and is a prime reason for dialysis in many developed countries. It is classified as a small blood vessel complication of diabetes.
Signs and symptoms
During its early course, diabetic nephropathy often has no symptoms. Symptoms can take 5 to 10 years to appear after the kidney damage begins. These late symptoms include severe tiredness, headaches, a general feeling of illness, nausea, vomiting, frequent voiding, lack of appetite, itchy skin, and leg swelling.
The cause of diabetic nephropathy is not well understood, but it is thought that high blood sugar, advanced glycation end product formation, and cytokines may be involved in the development of diabetic nephropathy.
Kidney damage is likely if one or more of the following is present:
- Poor control of blood glucose
- High blood pressure
- Type 2 diabetes mellitus (after age 30)
- History of cigarette smoking
- A family history of kidney problems
Diabetes causes a number of changes to the body's metabolism and blood circulation, which likely combine to produce excess reactive oxygen species (chemically reactive molecules containing oxygen). These changes damage the kidney's glomeruli (networks of tiny blood vessels), which leads to the hallmark feature of albumin in the urine (called albuminuria). As diabetic nephropathy progresses, a structure in the glomeruli known as the glomerular filtration barrier (GFB) is increasingly damaged. This barrier is composed of three layers including the fenestrated endothelium, the glomerular basement membrane, and the epithelial podocytes. The GFB is responsible for the highly selective filtration of blood entering the kidney's glomeruli and normally only allows the passage of water, small molecules, and very small proteins (albumin does not pass through the intact GFB). Damage to the glomerular basement membrane allows proteins in the blood to leak through, leading to accumulation in Bowman's space as distinct periodic-acid schiff positive nodules called Kimmelstiel–Wilson nodules.
|CKD Stage||eGFR level (mL/min/1.73 m2)|
|Stage 1||≥ 90|
|Stage 2||60 – 89|
|Stage 3||30 – 59|
|Stage 4||15 – 29|
|Stage 5||< 15|
- Normal albuminuria: urinary albumin excretion <30 mg/24h;
- Microalbuminuria: urinary albumin excretion in the range of 30–299 mg/24h;
- Clinical (overt) albuminuria: urinary albumin excretion ≥300 mg/24h.
People with diabetes are recommended to have their albumin levels checked annually, beginning immediately after diagnosis for type 2 diabetics, and five years after diagnosis for type 1 diabetics. To test kidney function, the person's estimated glomerular filtration rate (eGFR) is measured from a blood sample. Normal eGFR ranges from 90 to 120 ml/min/1.73 m2.
The goals of treatment are to slow the progression of kidney damage and control related complications. The main treatment, once proteinuria is established, is ACE inhibitor medications, which usually reduce proteinuria levels and slow the progression of diabetic nephropathy. Other issues that are important in the management of this condition include control of high blood pressure and blood sugar levels (see diabetes management), as well as the reduction of dietary salt intake.
Diabetic nephropathy in type 2 diabetes can be more difficult to predict because the onset of diabetes is not usually well established. Without intervention, 20-40 percent of patients with type 2 diabetes/microalbuminuria, will evolve to macroalbuminuria.
Diabetic nephropathy is the most common cause of end-stage kidney disease, which may require hemodialysis or even kidney transplantation. It is associated with an increased risk of death in general, particularly from cardiovascular disease.
In the U.S., diabetic nephropathy affected an estimated 6.9 million people during 2005–2008. The number of people with diabetes and consequently diabetic nephropathy is expected to rise substantially by the year 2050.
- Kittell F (2012). "Diabetes Management". In Thomas LK, Othersen JB. Nutrition Therapy for Chronic Kidney Disease. CRC Press. p. 198.
- "diabetic nephropathy". Retrieved 2015-06-27.
- Longo et al., Harrison's Principles of Internal Medicine, 18th ed., p.2982
- "Diabetes and kidney disease: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2015-06-27.
- "Diabetic Nephropathy: Background, Pathophysiology, Etiology". 2015-06-20.
- Cao, Zemin; Cooper, Mark E (2011). "Pathogenesis of diabetic nephropathy". Journal of Diabetes Investigation. 2 (4): 243–247. doi:10.1111/j.2040-1124.2011.00131.x. ISSN 2040-1116. PMC . PMID 24843491.
- Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, et al. (2014). "Diabetic kidney disease: from physiology to therapeutics". J. Physiol. (Lond.). 592 (Pt 18): 3997–4012. doi:10.1113/jphysiol.2014.272328. PMID 24907306.
- Fink, Howard A.; Ishani, Areef; Taylor, Brent C.; Greer, Nancy L.; MacDonald, Roderick; Rossini, Dominic; Sadiq, Sameea; Lankireddy, Srilakshmi; Kane, Robert L. (2012). "Introduction".
- Lewis G, Maxwell AP (2014). "Risk factor control is key in diabetic nephropathy". Practitioner. 258 (1768): 13–7, 2. PMID 24689163.
- "CDC - Chronic Kidney Disease - Glossary". Retrieved 2015-07-02.
- Koroshi, A (2007). "Microalbuminuria, is it so important?". Hippokratia. 11 (3): 105–107. ISSN 1108-4189. PMC . PMID 19582202.
- "Glomerular filtration rate: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2015-07-02.
- Lim, Andy KH (2014). "Diabetic nephropathy – complications and treatment". International Journal of Nephrology and Renovascular Disease. 7: 361–381. doi:10.2147/IJNRD.S40172. ISSN 1178-7058. PMC . PMID 25342915.
- "Diabetic Nephropathy Treatment & Management: Approach Considerations, Glycemic Control, Management of Hypertension". 2015-06-20.
- Shlipak, Michael. "Clinical Evidence Handbook: Diabetic Nephropathy: Preventing Progression - American Family Physician". www.aafp.org. Retrieved 2015-06-27.
- Ding Y, Choi ME (January 2015). "Autophagy in diabetic nephropathy". J Endocrinol. 224 (1): R15–30. doi:10.1530/JOE-14-0437. PMC . PMID 25349246.
- Lizicarova D, Krahulec B, Hirnerova E, Gaspar L, Celecova Z (2014). "Risk factors in diabetic nephropathy progression at present". Bratisl Lek Listy. 115 (8): 517–21. doi:10.4149/BLL_2014_101. PMID 25246291.
- Pálsson R, Patel UD (2014). "Cardiovascular complications of diabetic kidney disease". Adv Chronic Kidney Dis. 21 (3): 273–80. doi:10.1053/j.ackd.2014.03.003. PMC . PMID 24780455.
- Lerma, Edgar V. (2014-01-01). Diabetes and Kidney Disease. Springer. ISBN 9781493907939.
- Lai, K. N.; Tang, S. C. W. (2011-06-08). Diabetes and the Kidney. Karger Medical and Scientific Publishers. ISBN 9783805597432.
- "Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis". www.crd.york.ac.uk. Retrieved 2015-07-02.
- Gross, Jorge L.; Azevedo, Mirela J. de; Silveiro, Sandra P.; Canani, Luís Henrique; Caramori, Maria Luiza; Zelmanovitz, Themis (2005). "Diabetic Nephropathy: Diagnosis, Prevention, and Treatment". Diabetes Care. 28 (1): 164–176. doi:10.2337/diacare.28.1.164. ISSN 0149-5992. PMID 15616252.